Pipeline Review: Large Potential Overactive Bladder Population Beckons
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
You may also be interested in...
Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.